We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain MetLife (MET) in Your Portfolio
Read MoreHide Full Article
MetLife Inc. (MET - Free Report) is poised for growth on the back of its strong underwriting revenues, solid balance sheet and superior operating profitability.
The company recently announced a trial run of a completely revamped claims process by the use of Blockchain technology. The process, if successful and put into application, will be much cheaper than the manual alternative. This could allow MetLife to spend less on administrative costs, and therefore generate greater earnings.
The stock carries a Zacks Rank #2 (Buy) and an impressive Value Score of A. Our research shows that stocks with a Value Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or #2 offer the best opportunities in the value investing space.
The stock has gained 11.2% in a year’s time, compared with the industry’s rise of 5.95%.
The following factors nakes the stock look attractive:
Low Leverage: The company’s long term debt-to-equity ratio of 23.7% is lower than the industry average of 43.6%. A low level of debt provides financial strength to it and cements investors’ confidence.
High Profitability: MetLife’s ROE is 10.2% compared with the industry average of 7.9%. The ratio has increased over the past three years.
Revision in Earnings Estimates: The stock has witnessed an upward revision in its 2019 and 2020 earnings estimates over the past 60 days. This movement reflects analysts’ optimism for the company. Also, its 2019 earnings will likely grow 4.1% year over year.
Financial Flexibility: Free cash flow per share for MetLife is 2.36 compared with the industry’s average of 2.17.
Other Stocks
Other stocks worth considering are American International Group, Inc. (AIG - Free Report) Loews Corp. (L - Free Report) and The Hartford Financial Services Group, Inc. (HIG - Free Report) . While American International and Loewssport a Zacks Rank #1, The Hartford Financial Services carries a Zacks Rank #2.
American International Group, Loews, and The Hartford have witnessed an upward revision in 2019 earnings estimates by 12.3%, 6.3% and 2%, respectively, over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Retain MetLife (MET) in Your Portfolio
MetLife Inc. (MET - Free Report) is poised for growth on the back of its strong underwriting revenues, solid balance sheet and superior operating profitability.
The company recently announced a trial run of a completely revamped claims process by the use of Blockchain technology. The process, if successful and put into application, will be much cheaper than the manual alternative. This could allow MetLife to spend less on administrative costs, and therefore generate greater earnings.
The stock carries a Zacks Rank #2 (Buy) and an impressive Value Score of A. Our research shows that stocks with a Value Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or #2 offer the best opportunities in the value investing space.
The stock has gained 11.2% in a year’s time, compared with the industry’s rise of 5.95%.
The following factors nakes the stock look attractive:
Low Leverage: The company’s long term debt-to-equity ratio of 23.7% is lower than the industry average of 43.6%. A low level of debt provides financial strength to it and cements investors’ confidence.
High Profitability: MetLife’s ROE is 10.2% compared with the industry average of 7.9%. The ratio has increased over the past three years.
Revision in Earnings Estimates: The stock has witnessed an upward revision in its 2019 and 2020 earnings estimates over the past 60 days. This movement reflects analysts’ optimism for the company. Also, its 2019 earnings will likely grow 4.1% year over year.
Financial Flexibility: Free cash flow per share for MetLife is 2.36 compared with the industry’s average of 2.17.
Other Stocks
Other stocks worth considering are American International Group, Inc. (AIG - Free Report) Loews Corp. (L - Free Report) and The Hartford Financial Services Group, Inc. (HIG - Free Report) . While American International and Loewssport a Zacks Rank #1, The Hartford Financial Services carries a Zacks Rank #2.
You can see the complete list of today’s Zacks #1 Rank stocks here.
American International Group, Loews, and The Hartford have witnessed an upward revision in 2019 earnings estimates by 12.3%, 6.3% and 2%, respectively, over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>